Premier Purchasing Partners, the group purchasing unit of Premier and Xoft, the provider of FDA-cleared Electronic Brachytherapy Systems, have entered into an exclusive three-year group purchasing contract, for brachytherapy systems.

The agreement, which is in effect through May 1, 2013, extends Premier members preferred pricing on Xoft’s Axxent Electronic Brachytherapy System for the treatment of breast, endometrial and skin cancers.

The Axxent eBx System is also FDA cleared for use in the treatment of surface cancers or conditions where radiation therapy is indicated, including intraoperative radiation therapy (IORT).

As a platform technology, the Axxent System is designed to deliver non-radioactive therapy directly to cancerous tissue with minimal radiation exposure to surrounding healthy tissue.

Premier and Xoft said that utilising a proprietary miniaturized X-ray source and robotic controller, treatment can be performed in minimally shielded therapeutic settings allowing the radiation oncologist and other medical personnel to be present during treatment delivery and minimising patient anxiety.

Michael Klein, president and CEO of Xoft, said: “Premier has a proven track record of providing the latest advances in women’s health, and we want to thank the Imaging and Radiation Oncology Committee for offering its members access to this important cancer treatment platform that delivers definitive treatment directly to the cancer tumor with minimal exposure to surrounding healthy tissues.

“This is yet another validation of both the clinical value of isotope-free electronic treatment for accelerated brachytherapy and IORT applications that has been strongly reinforced recently by multiple publications, including the recent TARGIT study.”